Millennium Management’s Skye Bioscience SKYE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$23.5K Sell
14,611
-10,205
-41% -$35.1K ﹤0.01% 5980
2026
Q2
$138K Sell
24,816
-7,459
-23% -$46.9K ﹤0.01% 5417
2026
Q1
$159K Sell
32,275
-15,285
-32% -$100K ﹤0.01% 5243
2025
Q4
$285K Sell
47,560
-2,737
-5% -$32K ﹤0.01% 5288
2025
Q3
$1.58M Sell
50,297
-8,544
-15% -$258K ﹤0.01% 4254
2025
Q2
$1.97M Buy
+58,841
New +$974K ﹤0.01% 3900
2024
Q4
– Sell
-49,298
Closed -$1.54M – 6553
2024
Q3
$1.54M Buy
+49,298
New +$2.21M ﹤0.01% 3937

Other funds holding SKYE

Millennium Management's SKYE Position: Q3 2026 in Review

Millennium Management reduced its Skye Bioscience (SKYE) stake by 41% in Q3 2026, selling an estimated $35.1K and leaving 14,611 shares worth $23.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5980.

Millennium Management first reported a position in SKYE in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.97M in Q2 2025. 31 funds tracked by Wall St. Rank hold SKYE as of Q3 2026.

  • Millennium Management held 14,611 shares of Skye Bioscience worth $23.5K as of Q3 2026.
  • Millennium Management sold 10,205 Skye Bioscience shares in Q3 2026, an estimated $35.1K.
  • Skye Bioscience made up ﹤0.01% of Millennium Management's portfolio in Q3 2026, its #5980 holding.
  • Millennium Management first reported a position in Skye Bioscience in Q3 2024 and has held it in 7 quarters since.
  • Millennium Management's Skye Bioscience position peaked at $1.97M in Q2 2025.
  • 31 funds tracked by Wall St. Rank held Skye Bioscience as of Q3 2026.

Based on Millennium Management's 13F filing for Q3 2026, filed 16 Nov 2026.